Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/207270
Authors: 
Böhler, Yvonne-Beatrice
Lamping, Christian
Wichardt, Philipp C.
Year of Publication: 
2019
Series/Report no.: 
CESifo Working Paper 7879
Abstract: 
This paper reports the results from a statistical analysis of pharmaceutical price negotiations in Germany, where the pricing system was changed in 2011 in order to tie prices more to the benefits of the pharmaceuticals. A multiple linear regression of 187 pharmaceuticals which were assessed from 2011 to 2017 suggests that, despite the change, the manufacturers' launch strategy (freely chosen first year price) still has a major impact on pricing while the impact of the additional benefit remains comparably small. Moreover, the data suggest that the assessment of the Federal Joint Committee - while not yet existing at the point - best explains the manufacturer's launch strategy, indicating that manufacturers know more than they reveal.
Subjects: 
AMNOG
early benefit
assessment
pharmaceuticals
JEL: 
I10
Document Type: 
Working Paper

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.